| Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 … C Allemani, T Matsuda, V Di Carlo, R Harewood, M Matz, M Nikšić, ... The Lancet 391 (10125), 1023-1075, 2018 | 5199 | 2018 |
| Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ... Journal of clinical oncology 31 (27), 3327-3334, 2013 | 3853 | 2013 |
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open … YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ... The lancet oncology 15 (2), 213-222, 2014 | 2407 | 2014 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1821 | 2015 |
| Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ... New England Journal of Medicine 383 (14), 1328-1339, 2020 | 1450 | 2020 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ... The Lancet 389 (10072), 917-929, 2017 | 1286 | 2017 |
| Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 … JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ... The lancet oncology 16 (7), 830-838, 2015 | 1053 | 2015 |
| Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft, MJ Ahn, ... JAMA oncology 6 (5), 661-674, 2020 | 591 | 2020 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 583 | 2018 |
| Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study ML Johnson, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, ... Journal of Clinical Oncology 41 (6), 1213-1227, 2023 | 270 | 2023 |
| LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung … JCH Yang, MH Schuler, N Yamamoto, KJ O'Byrne, V Hirsh, T Mok, ... Journal of Clinical Oncology 30 (18_suppl), LBA7500-LBA7500, 2012 | 265 | 2012 |
| Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC D Planchard, PA Jänne, Y Cheng, JCH Yang, N Yanagitani, SW Kim, ... New England Journal of Medicine 389 (21), 1935-1948, 2023 | 254 | 2023 |
| Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children … A Bonaventure, R Harewood, CA Stiller, G Gatta, J Clavel, DC Stefan, ... The Lancet Haematology 4 (5), e202-e217, 2017 | 244 | 2017 |
| Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials JCH Yang, LV Sequist, C Zhou, M Schuler, SL Geater, T Mok, CP Hu, ... Annals of Oncology 27 (11), 2103-2110, 2016 | 203 | 2016 |
| IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD … D Spigel, F De Marinis, G Giaccone, N Reinmuth, A Vergnenegre, ... Annals of Oncology 30, v915, 2019 | 169 | 2019 |
| The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2) M Matz, MP Coleman, M Sant, MD Chirlaque, O Visser, M Gore, ... Gynecologic oncology 144 (2), 405-413, 2017 | 153 | 2017 |
| Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2) M Matz, MP Coleman, H Carreira, D Salmerón, MD Chirlaque, C Allemani, ... Gynecologic oncology 144 (2), 396-404, 2017 | 152 | 2017 |
| ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer D Planchard, N Reinmuth, S Orlov, JR Fischer, S Sugawara, S Mandziuk, ... Annals of Oncology 31 (5), 609-618, 2020 | 138 | 2020 |
| LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation … YL Wu, C Zhou, CP Hu, JF Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ... Journal of Clinical Oncology 31 (15_suppl), 8016-8016, 2013 | 119 | 2013 |
| Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut … JCH Yang, LV Sequist, MH Schuler, T Mok, N Yamamoto, KJ O'Byrne, ... Journal of Clinical Oncology 32 (15_suppl), 8004-8004, 2014 | 105 | 2014 |
Sergey OrlovResearch Institute of Medical PrimatologyEmail verificata su primatologia.ru
